- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02712606
Accuracy of Pulse Oximeter With Hypoxemic Measurements (bluesensor)
April 4, 2018 updated by: Jin-Tae Kim, Seoul National University Hospital
A Study About Accuracy of Pulse Oximeter With Hypoxemic Measurements (Blue Sensor) in Children With Cyanotic Congenital Heart Disease
A study about accuracy of pulse oximeter with hypoxemic measurements (Blue sensor, Masimo, Irvine, CA, USA) in children with cyanotic congenital heart disease
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
280
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 110-744
- Seoul National University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
tertiary care university children's hospital
Description
Inclusion Criteria:
- clinical diagnosis of cyanotic congenital heart disease
- weight 2.5kg to 30kg
- undergoing general anesthesia
- preoperative SpO2<97%
Exclusion Criteria:
- none
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
accuracy of pulse oximetry using blue sensor
Time Frame: From the start of anesthetic induction until discharge from hospital, assessed up to 1 week.
|
Each arterial blood gas sample and pulse oximeter oxygen saturation (SpO2) from blue sensor pulse oximetry are simultaneously obtained if the SpO2 is <97%.
|
From the start of anesthetic induction until discharge from hospital, assessed up to 1 week.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2016
Primary Completion (Actual)
March 1, 2017
Study Completion (Actual)
December 1, 2017
Study Registration Dates
First Submitted
March 9, 2016
First Submitted That Met QC Criteria
March 14, 2016
First Posted (Estimate)
March 18, 2016
Study Record Updates
Last Update Posted (Actual)
April 5, 2018
Last Update Submitted That Met QC Criteria
April 4, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-1602-060-740
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cyanotic Congenital Heart Disease
-
Assiut UniversityUnknownCongenital; Cyanotic Heart Disease
-
Cukurova UniversityCompletedPediatric HD | Cyanotic Congenital Heart DiseaseTurkey
-
University of California, DavisCompletedCyanotic Congenital Heart DiseaseUnited States
-
Universitas Sumatera UtaraIndonesia UniversityCompletedCyanotic Congenital Heart DiseaseIndonesia
-
University of California, San DiegoTerminatedAnemia | Congenital Heart Disease | Cyanotic Congenital Heart Disease | CyanosisUnited States
-
Lifetech Scientific (Shenzhen) Co., Ltd.UnknownFeasibility, Efficacy and Safety of IBS ® for Implantaiton in the PDA in Duct-dependent Cyanotic CHDPatent Ductus Arteriosus | Duct-dependent Cyanotic Congenital Heart DiseaseMalaysia
-
University of California, DavisCompletedCyanotic Congenital Heart DiseaseUnited States
-
Great Ormond Street Hospital for Children NHS Foundation...CompletedCalprotectin | Cyanotic Heart DiseaseUnited Kingdom
-
Baylor College of MedicineCompletedCongenital Heart Disease | Cardiac Disease | Hypoplastic Left Heart | Cyanotic Congenital Heart DiseaseUnited States
-
Stanford UniversityCompletedCyanotic Heart DiseaseUnited States